
This week’s article highlights research out of Colorado State University that identifies a potential anti-TB compound against a unique target– the inner membrane transporter MmpL3 of Mycobacterium tuberculosis–that inhibits an essential cell function of the mycobacteria. Additional links to TB R&D News are included.
With government budget shortfalls and looming funding cuts, priorities across the public sector are being scrutinized especially with relation to scientific and medical research which represents only 2% of the total federal budget in the U.S. This month, two articles published in separate journals by different groups with different objectives address the role of the public sector in the development of pharmaceuticals. Both articles found that the public sector does have impact in this area especially for innovative drugs and biologics.
The FDA issued a draft guidance for the drug industry entitled “Guidance for Industry Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination.” This is exciting news for TB drug development, since there is the potential to reduce the time to develop and obtain approval for new regimens by several years. The FDA is accepting comments from the public until February 14, 2011.